Gilead Sciences

News

ASCO 25: Gilead eyes first-line use of Trodelvy in TNBC

Gilead lays down a marker for AZ and Daiichi Sankyo to follow as Trodelvy scores in first-line treatment of triple-negative breast cancer (TNBC).

News

Gilead Sciences' chief executive Daniel O'Day

Gilead ups its US investment plans by $11 billion

Gilead Sciences has joined the list of pharma groups hiking their capital investment plans in the US.

News

Women & HIV ambassador, Iris, on a block 'I' in 'HIV'

UK's HIV response is 'failing women'

Women are being overlooked in the UK's HIV response and can face barriers to accessing prevention, testing and care, says a new campaign.

News

Vials on a conveyor belt - pharma manufacturing

Trodelvy-Keytruda pairing hits the spot in breast cancer

Gilead Sciences has cemented the role of its TROP2 drug Trodelvy in triple-negative breast cancer with a study win in combination with MSD's Keytruda.

Patients

How pharma is tackling new direct-to-patient programmes

At Reuters Pharma USA, executives from AstraZeneca, Gilead, Kyowa Kirin, and EVERSANA discussed the what, why, and how of direct-to-patient models.

News

FDA sets June date for Gilead's twice-yearly HIV PrEP

Gilead's already dominant position in HIV PrEP could be extended if the FDA approves a new twice-yearly injectable product later this year.

ASCO 25: Gilead eyes first-line use of Trodelvy in TNBC

Gilead ups its US investment plans by $11 billion

UK's HIV response is 'failing women'

Trodelvy-Keytruda pairing hits the spot in breast cancer

How pharma is tackling new direct-to-patient programmes

FDA sets June date for Gilead's twice-yearly HIV PrEP

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Gilead Sciences

Editor's Picks